These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21439443)

  • 1. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
    Trojano M; Paolicelli D; Tortorella C; Iaffaldano P; Lucchese G; Di Renzo V; D'Onghia M
    Neurol Clin; 2011 May; 29(2):309-21. PubMed ID: 21439443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Carroll WM
    Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS
    Neurology; 2011 Jan; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pediatric multiple sclerosis and variants.
    Pohl D; Waubant E; Banwell B; Chabas D; Chitnis T; Weinstock-Guttman B; Tenembaum S;
    Neurology; 2007 Apr; 68(16 Suppl 2):S54-65. PubMed ID: 17438239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gap between effect of drugs and effectiveness of treatments.
    Sorensen PS
    J Neurol Sci; 2007 Aug; 259(1-2):128-32. PubMed ID: 17362994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C; Prosperini L; Sbardella E; Paolillo A
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives in the natural history of multiple sclerosis.
    Tremlett H; Zhao Y; Rieckmann P; Hutchinson M
    Neurology; 2010 Jun; 74(24):2004-15. PubMed ID: 20548045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of multiple sclerosis: update 1998.
    Weinshenker BG
    Semin Neurol; 1998; 18(3):301-7. PubMed ID: 9817534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.
    Katrych O; Simone TM; Azad S; Mousa SA
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):512-9. PubMed ID: 19811446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding.
    Ferrero S; Esposito F; Pretta S; Ragni N
    Expert Rev Neurother; 2006 Dec; 6(12):1823-31. PubMed ID: 17181429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising emerging therapies for multiple sclerosis.
    Giovannoni G
    Neurol Clin; 2011 May; 29(2):435-48. PubMed ID: 21439452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.